Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

4(57.1%)

Phase 2

2(28.6%)

Phase 4

1(14.3%)

7Total

N/A(4)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04701034Phase 2Completed

Intravenous Immunoglobulin and Prednisolone for RPL After ART.

Role: collaborator

NCT04633694Not ApplicableCompleted

Insect Protein and Muscle Protein Signaling

Role: collaborator

NCT03490565Not ApplicableActive Not Recruiting

PREoperativ Study of Exercise Training

Role: collaborator

NCT02823613Not ApplicableCompleted

The Influence of High and Low Salt on Exosomes in the Urine

Role: collaborator

NCT04144270Unknown

The Importance of Muscle Function in Patients With Disseminated Bladder Cancer

Role: collaborator

NCT00925899Phase 2Completed

Melatonin for Fatigue and Other Symptoms in Patients With Advanced Cancer

Role: collaborator

NCT01711892Not ApplicableCompleted

Health Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy

Role: collaborator

NCT00851565Phase 4Unknown

Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy

Role: collaborator

All 8 trials loaded